Transforming Molecular Diagnostics through NanoTechnology

Informazioni relative al progetto

UbiHealth

ID dell’accordo di sovvenzione: 101188322

DOI

10.3030/101188322

Data della firma CE 20 Novembre 2024

Data di avvio 1 Dicembre 2024

Data di completamento 30 Novembre 2026

Finanziato da

• The European Innovation Council (EIC)

Costo totale

Nessun dato

Contributo UE

€ 2 499 999,00

Coordinato da

ALTRATECH LIMITED
Ireland

Periodic Reporting for period 1 - UbiHealth (Transforming Molecular Diagnostics through NanoTechnology)

Periodo di rendicontazione: 2024-12-01 al 2025-11-30

Sintesi del contesto e degli obiettivi generali del progetto

Project Summary
Altratech introduce a completely new method of molecular detection. This is a first-of-kind, multianalyte DNA, RNA, antibody and antigen diagnostic. It delivers concurrent serology and nucleic acid detection. The technology is compliant with the challenging demands of WHO REASSURED criteria, especially in providing a commercially viable diagnostic tool for the developing world.
The innovation is in the process of being productised by our sub-contractor The Cambridge Design Partnership (UK) into a fully automated, portable, stand-alone instrument for Point of Care and Point of Need. It will not require medically qualified personnel to operate. This innovation provides substantial advantages over existing, more complex, expensive and less portable Point of Care systems for the management of viral infections such as HIV, Hepatitis, Influenza, Malaria, Meningitis, Shingles, Dengue Fever, HPV, EBV-related cancers, and many more.
The Value Proposition to our target customers, who will be the world’s leading diagnostic companies, is the ability to licence a novel patent protected product, with a wider range of market applications compared to their current diagnostic products. This will facilitate their entry into new markets and increase gross margins in existing markets. This innovation will impact the €48B Diagnostics industry.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

•Isothermal (Recombinase Polymerase Amplification) protocol developed, detecting down to 1000 copies/mL from whole blood, and four other concentrations from whole blood and plasma.
•A filtration system provided a practical method of plasma separation and using this workflow, reliably detected HIV RNA at 1,000 copies/mL on the Altratech CMOS chip cartridge.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Altratech Detection Cartridge showed greater sensitivity than gold-standard optical detection at very low copy numbers (≥ 50 copies/mL).